Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rituxan · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Rituxan | DRUG | Given intravenously once weekly for four weeks. |
| 1018 ISS | DRUG | Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given. |
Inclusion Criteria: * 18 years of age or older * Pathological evidence of CD20+, B-cell follicular non-Hodgkin's lymphoma * Received at least one previous chemotherapy regimen for lymphoma * Hemoglobin \> 8.5 g/dl * WBC \> 2,000/mm3 * ANC \> 1,000/mm3 * Platelet count \> 75,000/mm3 * ECOG performan...
Rituxan is used for the treatment of Non-Hodgkin's Lymphoma, specifically B-cell follicular lymphoma. It is being studied in combination with an investigational immunostimulatory sequence (ISS) in a Phase 2 clinical trial. The drug is developed by Dynavax Technologies Corporation.
Rituxan is developed by Dynavax Technologies Corporation, a biopharmaceutical company traded under the ticker DVAX. The company is conducting clinical research on Rituxan for Non-Hodgkin's Lymphoma, with a completed Phase 2 trial evaluating its use in patients with B-cell follicular lymphoma.
Rituxan is in Phase 2 clinical development for Non-Hodgkin's Lymphoma. A Phase 2 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities, and its safety and efficacy are still being evaluated in clinical studies.
Rituxan has been studied in a Phase 2 clinical trial with the identifier NCT00251394. The trial, titled 'Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma,' enrolled 30 participants in the United States. The study is completed and was not randomized or blinded.
No, Rituxan is not the same as 1018 ISS. Rituxan is the drug being studied, while 1018 ISS is an investigational immunostimulatory sequence used in combination with Rituxan in the clinical trial. The trial evaluated the effects of 1018 ISS following Rituxan treatment in patients with B-cell follicular lymphoma.